Luminary Therapeutics, Inc.

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 2
BCMA / TACICell therapy
Multiple Myeloma
Phase 1
BCMA, BAFF-R (TNFRSF13C), TACI (TNFRSF13B)Cell therapy
Multiple Myeloma

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2030 (1)
December 2030 (1)
LMY-920Phase 2Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin Lymphoma, B-cell …
Est. primary completion 2030-12 · NCT07771361 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.